RxDoctor Payments Data

Matthew Breeding, DO

Internal Medicine · Whitesburg, KYNPI 1336450659

Payments from drug & device makers

$683in general payments, 2019–2025

Across 40 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$89
  • Novartis$74
  • AstraZeneca$69
  • AbbVie$68
  • Novo Nordisk$61
  • Indivior Inc.$51
  • plus $271 from 13 others

What the payments were for

  • Food & beverage$67298%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$683 in reported general payments places this provider in the 55th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$38,432
Medicare patients
168
Services billed
1,219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol175$136,019
JanuviaSitagliptin Phosphate109$115,540
MounjaroTirzepatide85$83,130
OzempicSemaglutide74$82,643
EliquisApixaban90$70,281
JardianceEmpagliflozin77$64,804
TrulicityDulaglutide47$46,212
Combivent RespimatIpratropium/Albuterol Sulfate49$31,253
LinzessLinaclotide42$30,795
XareltoRivaroxaban35$27,727
Spiriva HandihalerTiotropium Bromide33$25,391
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$23,824
Breztri AerosphereBudesonide/Glycopyr/Formoterol30$19,409
RybelsusSemaglutide15$18,159
SymbicortBudesonide/Formoterol Fumarate59$17,274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Bevespi Aerosphere$69$177,368275 claims
Lilly USA, LLCMounjaro, Trulicity$89$129,342132 claims
Novo NordiskOzempic, Rybelsus$61$100,80289 claims
PfizerEliquis$11$70,28190 claims
GSKTrelegy Ellipta, Anoro Ellipta$50$35,71644 claims
AbbVieLinzess$68$30,79542 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Whitesburg

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →